Gene Regulation Is Poised for Change, Easing Restrictions on Health Industries and Academic Research | Featured Article Selections (AI Translation)

基因监管酝酿变革 为大健康产学研松绑｜特稿精选

China is set to ease regulations on human genetic resources. Over the past year, the National Health Commission has taken over management duties from the Ministry of Science and Technology, marking a significant shift aimed at improving the regulatory framework [para. 1]. This reorganization indicates China's intent to stimulate scientific research and biopharmaceutical industry growth by optimizing administrative processes and enhancing regulatory efficiency [para. 3][para. 4].

Human genetic resources encompass genetic materials such as organs, tissues, and cells, plus the data derived from them [para. 4]. This resource is heavily regulated, impacting research institutions, medical facilities, and pharmaceutical companies, all of which must interact with the Office of Human Genetic Resources Administration of China (HGRAC) for permits related to sample collection, preservation, exportation, and international cooperation [para. 5].

Historically, China's genetic resource management has evolved over decades. In the 1990s, guidelines and administrative frameworks were relatively lax, leading to instances of bypassing oversight [para. 6][para. 7]. Significant regulatory tightening began around 2015 with the introduction of new laws such as the "Regulations on the Management of Human Genetic Resources" in 2019 and the "Biosecurity Law" in 2020 [para. 8]. This strict regulatory era faced criticism as rigorous approval processes delayed multi-center clinical trials and hindered international collaborations [para. 9][para. 10].

Notably, the management of genetic resources also faced corruption issues, exemplified by the disciplinary review and investigation of a top official, Sun Yanrong, in 2020 [para. 14]. Her trial highlighted the need for streamlining administration and delegating powers to avoid abuse [para. 15]. Subsequently, reforms began to address overextended regulations and imprecise risk controls, evident in revised "Implementation Rules" and other regulatory updates [para. 16].

Despite these reforms, challenges persist in balancing regulation and promoting industry-academia-research collaboration. Unclear guidelines and heavy-handed oversight continue to stifle scientific pursuits and biotechnology advancements [para. 18]. Experts argue that fundamental issues such as the interpretation of concepts like "biosecurity" and "genetic weapons" need to be clarified to mitigate public misunderstandings and avoid overregulation [para. 19].

The biopharmaceutical industry, deeply impacted by current regulations, is advocating for changes. Innovative companies struggle with lengthy approval processes and regulatory ambiguities [para. 10]. The launch of drug review reforms in 2015 reduced approval periods significantly, aligning them with international standards, yet the additional human genetic resources approval often nullifies these gains [para. 41].

Industry leaders call for regulatory refinements, highlighting the need to streamline approval processes further for human genetic resources. Suggestions include narrowing scope and delegating more authority for domestic trials and cooperation with international entities [para. 42]. There remains a critical need to distinguish between routine and significant genetic data to prevent delays in research and innovation [para. 53].

Global practices provide a benchmark for China. Countries like the U.K. exemplify how comprehensive genetic data collection and sharing, with clear regulations and open databases, spur research and economic growth [para. 70][para. 83]. Meanwhile, new regulations proposed in China aim to reduce bureaucratic burdens while maintaining national security, following feedback from various stakeholders [para. 59].

The regulation and utilization of human genetic resources are essential to China's biopharmaceutical and scientific advancement. Ensuring a balance between stringent oversight and promoting research and innovation remains a key challenge, as policymakers endeavor to reform existing frameworks with comprehensive and clear rules [para. 84][para. 91]. This ongoing reform process represents a significant step toward fostering a more conducive environment for scientific and industrial advancements in the field of biotechnology.